Brainsway Valuation
| BWAY Stock | USD 10.62 0.15 1.43% |
At this time, the firm appears to be fairly valued. Brainsway shows a prevailing Real Value of $10.21 per share. The current price of the firm is $10.62. Our model approximates the value of Brainsway from analyzing the firm fundamentals such as profit margin of 0.02 %, and Return On Equity of 0.0144 as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Brainsway's price fluctuation is somewhat reliable at this time. Calculation of the real value of Brainsway is based on 3 months time horizon. Increasing Brainsway's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Brainsway is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Brainsway Stock. However, Brainsway's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.62 | Real 10.21 | Hype 10.62 | Naive 10.27 |
The intrinsic value of Brainsway's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Brainsway's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Brainsway helps investors to forecast how Brainsway stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Brainsway more accurately as focusing exclusively on Brainsway's fundamentals will not take into account other important factors: Brainsway Total Value Analysis
Brainsway is currently forecasted to have valuation of 156.64 M with market capitalization of 204.31 M, debt of 471 K, and cash on hands of 49.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Brainsway fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
156.64 M | 204.31 M | 471 K | 49.62 M |
Brainsway Investor Information
About 19.0% of the company shares are held by institutions such as insurance companies. The book value of Brainsway was currently reported as 1.25. The company had not issued any dividends in recent years. Based on the key measurements obtained from Brainsway's financial statements, Brainsway is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Brainsway Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Brainsway suggests not a very effective usage of assets in January.Brainsway Ownership Allocation
Brainsway holds a total of 18.82 Million outstanding shares. Almost 80.78 percent of Brainsway outstanding shares are held by general public with 19.22 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Brainsway Profitability Analysis
The company reported the previous year's revenue of 31.79 M. Net Loss for the year was (4.2 M) with profit before overhead, payroll, taxes, and interest of 27.26 M.About Brainsway Valuation
Our relative valuation model uses a comparative analysis of Brainsway. We calculate exposure to Brainsway's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Brainsway's related companies.Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 118 people.
Brainsway Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.6 M | |
| Forward Price Earnings | 58.1395 |
Additional Tools for Brainsway Stock Analysis
When running Brainsway's price analysis, check to measure Brainsway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainsway is operating at the current time. Most of Brainsway's value examination focuses on studying past and present price action to predict the probability of Brainsway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainsway's price. Additionally, you may evaluate how the addition of Brainsway to your portfolios can decrease your overall portfolio volatility.